SUBSCRIBE
SUBSCRIBE
News   Drug Development

Vertex Pharmaceuticals (MA) Hepatitis C Drug, Telaprevir Achieves 75% Cure Rate in Study

May 26, 2010 | 
1 min read
Reuters -- A hepatitis C treatment being developed by Vertex Pharmaceuticals Inc led to a 75 percent cure rate in a pivotal trial of previously untreated patients, the company said on Tuesday.
Clinical research Phase 3
Vertex Pharmaceuticals
MORE ON THIS TOPIC
3D Vector Rocket launching from a gift box with coins and sparkles, Business growth, Finance success, Innovation, Promotion, and Profit expansion concept. Eps 10 Vector.
Funding
Sofinnova, Sanofi alum unveil Bionyra with $165M and next-gen immunology assets
June 22, 2026
 · 
2 min read
 · 
Gabrielle Masson
Neuroscience
UniQure’s chronic epilepsy gene therapy ‘should be on investors’ radar’
June 22, 2026
 · 
3 min read
 · 
Tristan Manalac
Purple neon arrow with glowing light trails and dynamic motion effect on dark background
ALS
Nura raises $73.8M to target ALS through a unique target
June 22, 2026
 · 
4 min read
 · 
Michael Gibney
Car silhouette in speed motion lines in vector
FDA
Denali sells FDA voucher for $195M to support neurodegenerative pipeline
June 19, 2026
 · 
1 min read
 · 
Annalee Armstrong